NEW HAVEN, Conn., Jan. 18, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (Biohaven or the “Company”) and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may pr…
